Sanofi launches multiple sclerosis treatment drug in India

07 Aug 2018 Evaluate

Sanofi’s specialty care global business unit -- Sanofi Genzyme has launched its multiple sclerosis treatment drug ‘Aubagio’ in India. The drug offers patients diagnosed with multiple sclerosis the efficacy and convenience of once-a-day oral treatment.

Aubagio is a differentiated disease modifying therapy that blocks the enzyme involved in multiplication of overactive immune cells.

Sanofi, a global and diversified healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients’ needs. Sanofi has core strengths in the field of healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, rare diseases, consumer healthcare, emerging markets and animal health.

Sanofi India Share Price

6052.95 -28.20 (-0.46%)
22-Nov-2024 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1797.80
Dr. Reddys Lab 1213.90
Cipla 1486.30
Lupin 2069.95
Zydus Lifesciences 948.70
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.